



Vineet Laboratories Limited

Regd. Office: SY. No. 11/A3, Saheb Nagar, Kurdu Vili, Chintal Kuntia, Eshwaramma Nilayam, L B Nagar Hyderabad.
CIN- L24304TG2016PLC112888
Phone: 040-24128833; Email Id: cs@vineetlabs.co.in; Website: vineetlabs.co.in

February 12, 2025

To
The General Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai-400001.

To
The Manager,
Listing Department,
**National Stock Exchange of India
Limited**,
Exchange Plaza, 5th Floor, Plot No – C/1,
G Block, Bandra Kurla Complex,
Bandra (East), Mumbai -400 051.

Scrip Code – 543298

Scrip Code - VINEETLAB

Dear Sir/Ma'am,

Sub: Outcome of Board Meeting held on Wednesday, February 12, 2025 as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of the company in its meeting held today i.e., on February 12, 2025 has:

- Considered and approved Un-audited Standalone Financial Results of the Company for the third quarter and nine months ended on December 31, 2024.

The Board Meeting commenced at 04:00 PM and concluded at 05:15 PM.

This is for your information and records.

Regards,

For Vineet Laboratories Limited

Gaddam Venkata Ramana
Managing Director
DIN: 00031873



VINEET LABORATORIES LIMITED
CIN:L24304TG2016PLC112888

SY. No. 11/A3, Eshwaramma Nilayam, Saheb Nagar, Kurdu Vill, Chintal Kunta, LB Nagar, Hyderabad, Telangana-500074, India.

Statement of Unaudited Financial Results for the quarter and Nine Months ended 31 December 2024

(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)


S No	Particulars	Quarter ended			9 Months ended		Year ended
		31 December 2024	30 September 2024	31 December 2023	31 December 2024	31 December 2023	31 March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	a) Net Sales/income from operations	1,809.93	1,895.76	3,264.70	6,091.86	11,354.27	15,059.13
II	b) Other income	3.26	20.02	1.25	60.54	5.24	46.32
III	Total Income (I + II)	1,813.19	1,915.78	3,265.95	6,152.40	11,359.51	15,105.44
VI	Expenses						
	a) Cost of material consumed	1,806.85	1,625.46	2,978.16	5,106.19	9,183.32	13,170.41
	b) Changes in inventories of finished goods, work-in progress and stock-in-trade(increase)/decrease	(79.94)	(281.50)	(348.28)	(139.34)	(431.42)	(1,778.50)
	c) Employee benefits expense	121.25	129.43	176.65	398.50	456.54	638.47
	d) Finance costs	95.14	98.98	107.68	307.77	306.02	478.10
	e) Depreciation and amortisation expenses	61.91	61.65	62.65	184.42	184.71	251.90
	f) Other expenses	375.36	453.04	522.32	1,250.28	1,767.36	2,308.72
	Total expenses	2,380.59	2,087.05	3,499.18	7,107.82	11,466.53	15,069.11
V	Profit/(loss) before exceptional items and tax (III - IV)	(567.39)	(171.27)	(233.23)	(955.43)	(107.02)	36.34
VI	Exceptional items	-	-	-	-	-	-
VII	Profit/(loss) before Tax (V - VI)	(567.39)	(171.27)	(233.23)	(955.43)	(107.02)	36.34
VIII	Tax expense :						
	a. Current tax	-	-	(29.19)	-	(18.71)	12.23
	b. Taxes in respect of prior periods	-	-	-	-	-	(18.71)
	c. Deferred tax	3.30	11.57	2.54	11.18	1.37	(59.89)
IX	Profit/(loss) for the period (VII-VIII)	(570.70)	(182.84)	(206.58)	(966.61)	(89.68)	83.99
X	Other comprehensive income(OCI)						
	A.						
	(i) Items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	-
	B.						
	(i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	17.99
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	(4.53)
	Total other comprehensive income	-	-	-	-	-	13.46
XI	Total comprehensive income for the Period (IX+X)	(570.70)	(182.84)	(206.58)	(966.61)	(89.68)	97.45
XII	Paid-up Equity Share capital (Face Value of Rs. 10/- per share)	921.90	921.90	921.90	921.90	921.90	921.90
XIII	Other Equity	-	-	-	-	-	2,550.53
XIV	Earnings per equity share (of Rs. 10/- each) (not annualised for the quarters)						
	(i) Basic	(6.19)	(1.98)	(2.24)	(10.48)	(0.97)	0.91
	(ii) Diluted.	(6.19)	(1.98)	(2.24)	(10.48)	(0.97)	0.91

Notes

- The above unaudited financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- The above unaudited results have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their meeting held on 12 February 2025.
- The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The company operates in one reportable business segment i.e. Active pharmaceuticals ingredient and intermediates. Hence segment reporting as per Ind AS 108 is not applicable.
- The results for the quarter and nine months ended 31 December 2024 are also available on website of BSE Limited, NSE Limited and on the Company's website.
- Figures for the previous periods have been rearranged/ reclassified wherever necessary to conform to the current period presentation.

For and on Behalf of Board of Directors

Bh. Satyanarayana Raju
Whole time Director & CEO
DIN:02697880



Date: 12th February 2025
Place: Hyderabad.


Vineet Laboratories Limited
 Balance sheet for the year ended 31 December 2024
 (All amounts are in INR Lakhs except share data or unless otherwise stated)

	Notes	As at	
		31 December 2024	31 March 2024
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	2,611.62	2,691.53
(b) Financial assets			
(i) Investments	4	21.53	18.16
(ii) Other financial assets	5	141.85	141.95
(c) Other non-current assets	6	13.24	16.74
		2,788.24	2,868.38
Current assets			
(a) Inventories	7	5,262.97	4,939.37
(b) Financial assets			
(i) Trade receivables	8	986.20	3,160.39
(ii) Cash and cash equivalents	9	79.53	22.78
(iii) Bank balances other than (ii) above	10	21.23	21.23
(iv) Other financial assets	5	2.70	5.86
(c) Other current assets	6	422.42	669.19
		6,775.05	8,818.81
Total assets		9,563.29	11,687.20
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	11	921.90	921.90
(b) Other equity	12	1,583.92	2,550.53
		2,505.82	3,472.43
Liabilities			
Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	13	468.67	388.57
(b) Provisions	14	127.08	80.62
(c) Deferred tax liabilities (Net)	15	157.12	145.94
		752.87	615.13
Current liabilities			
(a) Financial liabilities			
(i) Borrowings	13	3,527.81	4,041.39
(ii) Trade payables	16		
- total outstanding dues of micro and small enterprises;		878.32	1,450.47
- total outstanding dues of creditors other than micro and small enterprises		1,614.64	1,775.30
(iii) Other financial liabilities	17	19.82	40.81
(b) Other current liabilities	18	264.00	232.97
(c) Provisions	14	-	46.46
(d) Current tax liabilities (net)	19	-	12.23
		6,304.60	7,599.63
Total equity and liabilities		9,563.30	11,687.20

The accompanying notes form an integral part of these financial statements.
 This is the Balance Sheet referred to in our report of even date.

For and on behalf of the Board of Directors of
 Vineet Laboratories Limited


 B. Satyanarayana Raju
 Whole time Director & CFO
 DIN: 02697880



Place: Hyderabad
 Date: 12.02.2025

Vineet Laboratories Limited

Statement of Profit and Loss for the year ended 31 December 2024


(All amounts are in INR Lakhs except share data or unless otherwise stated)

	Notes	For the period ended	
		31 December 2024	31 March 2024
Income			
Revenue from operations	20	6,091.86	15,059.13
Other income	21	60.54	46.32
Total income		6,152.40	15,105.44
Expenses			
Cost of material consumed	22	5,106.19	13,170.41
Changes in inventories of stock-in-trade	23	(139.34)	(1,778.50)
Employee benefits expense	24	398.50	638.47
Finance costs	25	307.77	478.10
Depreciation and amortisation expense	26	184.42	251.90
Other expenses	27	1,250.28	2,308.72
Total expenses		7,107.82	15,069.11
Profit Before Tax		(955.43)	36.34
Tax expenses			
Current tax expense	23	-	12.23
Deferred tax expense		11.18	(59.89)
Taxes in respect of prior periods		-	(18.71)
Total tax expenses		11.18	(66.37)
Profit for the year		(966.61)	102.71
Other Comprehensive Income ('OCI')			
(i) Items that will not be reclassified subsequently to profit or loss			
- Re-measurement gains/(losses) on defined benefit plans		-	1.85
- Income tax effect on the above		-	(0.47)
(ii) Items that will be reclassified subsequently to profit or loss			
		-	-
Total other comprehensive income		-	1.38
Total comprehensive income for the year		(966.61)	104.09
Earnings per equity share (EPES)			
Basic and Diluted EPES (in absolute ₹ terms)	24	(10.48)	1.11
Nominal value per equity share (in absolute ₹ terms)		10.00	10.00

The accompanying notes form an integral part of these financial statements.
This is the Statement of Profit and Loss referred to in our report of even date

For and on behalf of the Board of Directors of
Vineet Laboratories Limited

B. Satyanarayana Raju
B. Satyanarayana Raju
Whole time Director & CFO
DIN: 02697880



Place: Hyderabad
Date: 12.02.2025

**Independent Auditor's Review Report on the Quarter and nine months ended 31st December, 2024
Unaudited Standalone Financial Results of the Company pursuant to the Regulations 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To The Board of Directors of **VINEET LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **VINEET LABORATORIES LIMITED** ('the Company') for the quarter ended 31st December 2024 and the year to date results for the period from 01st April 2024 to 31st December 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations')
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements.



Our conclusion is not modified in respect of the above matters.

For NSVR & Associates LLP

Chartered Accountants

FRN: 008801S/S200060




V Gangadhara Rao N

Partner

Membership No: 219486

UDIN: 25219486BMIRTZ1884

Place: Hyderabad

Date: 12-02-2025